GTA 103
Alternative Names: CAR-NK cell therapy-Glycostem; GTA-103Latest Information Update: 17 Apr 2023
At a glance
- Originator Glycostem; HK inno.N
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
- Research Cancer
Most Recent Events
- 17 Apr 2023 Early research in cancer in Netherlands, prior to April 2023 (Parenteral) (Glycostem pipeline, April 2023)
- 23 Feb 2021 Preclinical trials in Glioblastoma in Netherlands (Parenteral) (Glycostem pipeline, February 2021)
- 23 Feb 2021 Preclinical trials in Glioblastoma in South Korea (Parenteral) (Glycostem pipeline, February 2021)